ABOUT THE PRODUCT
IN-006 is an inhaled antibody treatment designed to trap pathogens in the lung mucus, blocking their spread and facilitating their rapid elimination. It is currently in Phase 1b clinical trials for the treatment of COVID-19.
Information is owner-confirmed
Last updated 2 months ago
Price range
Other products/services from Inhalon Biopharma
IN-002
Biotechnology
N/A
Inhalon Biopharma
United States (US)